Aastrom Biosciences, Inc. (NASDAQ:ASTM)
The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.
Recs
waiting for the phase 3 results, go ASTM
Recs
strong insider buying
Recs
improves peoples lives with stem cells introduced into hearts making people regain their lives the heart increases its blood flow and people can walk and exercise again those peoplewho had very little chance even with heart surgery
Recs
Recs
rated buy. cell structure is the future?
Recs
While I am almost 100% skeptical of Garza's pump on biomedreports.com, I do find that ASTM will have a very good chance to demonstrate historical stem cell therapy first in CLI.
The interim data (n=46) was significant. But the number of patients was small, treatment time was only 6 months.
We will see the whole data set (n=86) on Nov 18. This is a phase IIb, randomized, placebo-controlled, and double-blinded trial. Half of patients will have a treatment of 12 months. We don't have to wait too long to see the data.
If the data is significant, ASTM will triple its price. There are numerous cases in biotech that may be called "black swans".
As the recent CLI trial by Sanofi/Vical has failed, the significance of ASTM stem cell therapy will be enormous should the data be good.
Let's wait and see.
Recs
DCM patient(see on the webpages of ASTM) is alive and well. Motley Fools report does not recognize that. And that is Insane. Who is paying you to discredit ASTM. You guys must be out of your mind, just like Cramer!!
Read the report by Scimitar and Zacks...
Recs
Going to phase 3 and promising result at phase 2B. Ischemia therapy - anything that improves patient condition at this stage is an improvement over amputation.
Recs
They will need time to get the studies done. This stuff works and very exciting to see it all come alive and make a lot of money investing....
Recs
Using audlt stem cells may take the edge off the whole stem cell debate. They will need to push hard the "adult" angle to come out a winner.
Recs
Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.
wyn harter
Recs
Flucuates between .50 and 5.00
Recs
legislation is pending improving funding to stem cell research companies, expect a gain in this market at least for the short term.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 14 of 14